ABBV vs V: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Visa Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-06.
AbbVie Inc. · Healthcare
$261.07
+1.2% upside to fair value
Grade C
High Quality
VS
Visa Inc. · Financial Services
$327.24
+27.8% upside to fair value
Grade A
High Quality
QuantHub Verdict
V has more upside to fair value
(+27.8%).
V trades at a lower forward P/E
(28.2x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
V |
| Current Price |
$261.07 |
$327.24 |
| Fair Value Estimate |
$264.30 |
$418.15 |
| Upside to Fair Value |
+1.2%
|
+27.8%
|
| Market Cap |
$461.3B |
$627.3B |
| Forward P/E |
128.0x
|
28.2x
|
| EV / EBITDA |
31.0x
|
22.6x
|
| Price / Sales |
7.3x
|
14.6x
|
| Price / FCF |
22.1x
|
29.6x
|
| Revenue Growth YoY |
+12.4%
|
+17.1%
|
| Gross Margin |
70.7%
|
81.3%
|
| Operating Margin |
27.6%
|
61.1%
|
| Return on Equity |
68.0%
|
58.9%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.52%
|
3.38%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology and aesthetics. The company is transitioning from its historical Humira dominance, which has faced loss of exclusivity, toward high-growth assets like Skyrizi and Rinvoq that are driving robust revenue growth of 12.4% in the most recent quarter. Despite strong revenue growth and a dura…
Visa Inc. operates a global payments network that facilitates electronic funds transfers worldwide, primarily through credit and debit cards. The company benefits from a very strong and widening moat driven by its extensive global card network and acceptance infrastructure, supported by a shareholder-friendly capital allocation policy including high buybacks and dividends. Visa's business quality…
Accumulation Zones
| Metric |
ABBV |
V |
| Zone Low |
$198.23 |
$313.61 |
| Zone High |
$224.66 |
$355.43 |
| In Buy Zone? |
No
|
Yes
|